OpGen

OpGen Gross Margin

The Gross Margin of OpGen (OPGN) as of Oct 20, 2026 is 90.00 %. In the previous year, Gross Margin was 99.36 % — a change of -9.42% (lower).

Gross Margin

90.00 %

YoY

-9.42%

Last updated:

Gross Margin of OpGen is 2025 90.00 % . Gross Margin of OpGen was 2024 99.36 % . It decreases by -9.42% lower compared to the previous year.

OpGen's gross margin stands at 90.0%, up from 33.9% several years earlier.

The OpGen Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
37.27 USD
Jan 1, 2019
53.36 USD
Jan 1, 2020
8.68 USD
Jan 1, 2021
33.86 USD
Jan 1, 2022
-31.34 USD
Jan 1, 2023
-2.65 USD
Jan 1, 2024
99.36 USD
Jan 1, 2025
90.00 USD
The OpGen Gross Margin history
YEARGross MarginYoY
90.00 %-9.42%
99.36 %-3,844.63%
-2.65 %-91.53%
-31.34 %-192.55%
33.86 %+289.90%
8.68 %-83.72%
53.36 %+43.16%
37.27 %+11.04%
33.57 %-22.15%
43.12 %-15.43%
50.98 %-33.75%
76.95 %+31,451.42%
0.24 %-164.56%
-0.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OpGen Stock analysis

What does OpGen do? OpGen, Inc. generates revenue through its Acuitas-branded high-resolution DNA tests and bioinformatics solutions, targeting healthcare providers and hospitals globally. The company's molecular diagnostics and informatics products help combat infectious diseases by providing precise diagnostic information on life-threatening infections and multidrug-resistant microorganisms. These solutions guide clinicians in managing patient outcomes and hospital biome protection through customized screening and surveillance. The firm's DNA tests and bioinformatics address antibiotic resistance, offering data-driven insights for healthcare decision-making. The company's Acuitas trade name is used for its high-resolution DNA tests, which are marketed to healthcare settings focused on infectious disease management. OpGen's products help hospitals manage patient care decisions and protect against the spread of infections caused by multidrug-resistant pathogens. The firm's global network of customers and partners includes healthcare providers seeking to implement pathogen surveillance systems for improved infection control. OpGen's business model centers on delivering molecular information solutions that combine DNA testing with bioinformatics, creating a comprehensive approach to infectious disease management. The company's focus on antibiotic resistance and multidrug-resistant microorganisms drives demand for its Acuitas products, which are positioned as tools for guiding clinical decisions and optimizing hospital infection control protocols. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

Gross Margin of OpGen is 90.00 % in 2025.

Gross Margin of OpGen changed from 99.36 % to 90.00 %, representing a -9.42% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin OpGen since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's OpGen with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — OpGen

All Key Metrics — OpGen